Clinical Trial Update: Pemetrexed and Gemcitabine in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating the combination of pemetrexed and gemcitabine in patients with advanced non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• Gemzar (gemcitabine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Lung Neoplasms | Phase 1, Phase 2 | Status: COMPLETED